Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
1.57B
-
Number of holders
-
68
-
Total 13F shares, excl. options
-
115M
-
Shares change
-
+4.59M
-
Total reported value, excl. options
-
$195M
-
Value change
-
+$7.48M
-
Put/Call ratio
-
0.64
-
Number of buys
-
25
-
Number of sells
-
-33
-
Price
-
$1.70
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) as of Q2 2022
85 filings reported holding ADAP - Adaptimmune Therapeutics PLC - Ordinary Shares as of Q2 2022.
Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) has 68 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 115M shares
of 1.57B outstanding shares and own 7.3% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (39M shares), NEA Management Company, LLC (17.1M shares), BAILLIE GIFFORD & CO (15.3M shares), BAKER BROS. ADVISORS LP (9.83M shares), PFM Health Sciences, LP (9.11M shares), Long Focus Capital Management, LLC (4.68M shares), Rock Springs Capital Management LP (2.36M shares), MORGAN STANLEY (2.08M shares), Endurant Capital Management LP (1.82M shares), and FMR LLC (1.58M shares).
This table shows the top 68 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.